Video

2020 IDSA Guidance for Treatment of Antimicrobial-Resistant Gram-Negative Infections Deprioritizes Polymyxin Use

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections. The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline."

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections. He also discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com